Sponsored Content

Initial results from Cynata Therapeutics’ (ASX:CYP) study using its mesenchymal stem cells (MSCs) to treat coronary artery disease (CAD) have been announced, and they’re very encouraging.

The study, carried out in collaboration with the University of New South Wales (UNSW), supports CYP’s CymerusTM stem cell platform in the use of therapies for CAD.

The early results from the study show that CYP’s stem cells induce neovascularation. In layman’s terms – the stem cells have encouraged the growth of new blood vessels.

The study was conducted in a well-accepted model system known to predict behaviour of the investigative product, in this case Cynata’s cells, in a living system. This is known in the industry as in-vitro assay.

What is CAD and why is it so dangerous?

CAD happens when arteries that supply blood to the heart muscle become clogged, hardened and narrowed, resulting in a reduction in the blood supply to the heart itself.

It is the most common cause of heart attacks – responsible for one-third of all deaths in people over the age of 35 in developed countries.

Furthermore, it is the leading cause of death in the US.

The heart then becomes starved of oxygen and nutrients and can no longer effectively pump blood around the body – leading to heart failure.

What did the study show?

The study modified the material that the cells were grown on and this modification was shown to improve the Cymerus MSCs’ ability to improve the growth of new blood vessels.

The research is being led by Dr Kristopher Kilian, ARC Future Fellow at the UNSW School of Chemistry and School of Materials Science and Engineering who said that the results were highly encouraging.

“In practical terms, these findings mean that Cynata’s Cymerus MSCs could potentially be used therapeutically to encourage healthy new blood vessel growth in the heart of patients in whom the existing blood supply has been compromised as a result of CAD,” said Kilian.

Flow of research to continue

CYP initially announced its collaboration with UNSW back in June 2018.

Under the terms of the collaboration, the parties are working together to develop methods for enhancing CYP’s stem cells ability to improve blood supply to the heart.

The study was progressed under a 50:50 cost-sharing agreement. UNSW and CYP provide in-kind and matching cash contributions.

UNSW’s Science Industry Network Seed Fund 2018 has funded its half of the costs.

Dr Kilian Kelly, Cynata’s Vice President of Product Development, was pleased with the results from the collaboration and is looking forward to determining the next steps for the development of the Cynata MSCs in the treatment of CAD.

“The use of designer cell culture materials to customise the therapeutic properties of MSCs holds great promise for specialised medical applications, including the treatment of CAD,” he said.

Cynata’s Cymerus technology offers several important advantages for the production of consistent and efficacious therapeutic MSCs,” he continued.

CYP’s MSCs have demonstrated positive preclinical results in multiple studies including in asthma, critical limb ischemia, heart attack and diabetic wounds.

The study is complementary to its heart attack research and CYP hopes that its stem cells can potentially be used to address CAD before a heart attack occurs.

 

This content is produced by Star Investing in commercial partnership with Cynata Therapeutics. This content does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.